Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 3/20 | 0.51 |
| ▸ | NMT1 | P30419 | 5/20 | 0.50 |
| ▸ | NMT2 | O60551 | 4/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952057 | 1.00 | SIRT6 (0.51) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL18715483 | 0.92 | TLR2 (0.48) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL18708300 | 0.92 | TLR2 (0.48) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL16234712 | 0.89 | NMT2 (0.53) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL16234693 | 0.89 | NMT2 (0.53) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL16259340 | 0.89 | NMT2 (0.53) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL16259323 | 0.89 | NMT2 (0.53) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL16234715 | 0.89 | NMT2 (0.53) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL16259360 | 0.89 | NMT2 (0.53) | SIRT6SIRT1TLR2NMT1NMT2 | |
| SCHEMBL16234694 | 0.89 | NMT2 (0.53) | SIRT6SIRT1TLR2NMT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3700545-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | Southern Research Institute (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | SIRT6 2383/4885SIRT1 1578/4885TLR2 417/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | SIRT6 2383/4885SIRT1 1578/4885TLR2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.